NeuroBo Pharmaceuticals IncNASDAQ:NRBO
- LAST PRICE4.1500
- TODAY'S CHANGE (%)0.0550 (1.3431%)
- Bid / Lots4.0100/ 30
- Ask / Lots4.2900/ 1
- Open / Previous Close4.0600 / 4.0950
- Day Range
- 52 Week Range
- Volume14,579
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRBO |
|---|---|---|
| 09:38 ET | 962 | 4.06 |
| 09:39 ET | 450 | 4.26 |
| 09:56 ET | 200 | 4.2365 |
| 09:57 ET | 100 | 4.2 |
| 10:06 ET | 104 | 4.168 |
| 10:14 ET | 100 | 4.07 |
| 10:35 ET | 218 | 4.1929 |
| 10:37 ET | 700 | 4.17 |
| 10:39 ET | 200 | 4.22 |
| 10:42 ET | 258 | 4.2352 |
| 10:44 ET | 324 | 4.2531 |
| 10:46 ET | 250 | 4.2585 |
| 10:50 ET | 118 | 4.2 |
| 10:51 ET | 250 | 4.19 |
| 11:08 ET | 237 | 4.24 |
| 11:11 ET | 200 | 4.23 |
| 12:20 ET | 100 | 4.19 |
| 12:25 ET | 1040 | 4.22 |
| 12:32 ET | 1000 | 4.225 |
| 12:45 ET | 348 | 4.259 |
| 12:48 ET | 100 | 4.26 |
| 01:50 ET | 100 | 4.25 |
| 02:06 ET | 405 | 4.2001 |
| 02:08 ET | 100 | 4.2 |
| 02:15 ET | 1295 | 4.2 |
| 02:56 ET | 300 | 4.2 |
| 03:02 ET | 100 | 4.14 |
| 03:16 ET | 934 | 4.2293 |
| 03:43 ET | 200 | 4.15 |
| 03:52 ET | 100 | 4.13 |
| 03:57 ET | 100 | 4.13 |
| 03:59 ET | 208 | 4.15 |
Jul 17, 2024
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now, from 7:00AM ET on Wednesday Jul 17, 2024 by Dow Jones
7:00AM ET on Wednesday Jul 17, 2024 by Dow Jones
Jul 11, 2024
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July, from 8:01AM ET on Thursday Jul 11, 2024 by Dow Jones
8:01AM ET on Thursday Jul 11, 2024 by Dow Jones
Jun 26, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NeuroBo Pharmaceuticals Inc | 33.7M | -1.3x | --- |
Quince Therapeutics Inc | 33.7M | -1.0x | --- |
Achilles Therapeutics PLC | 34.4M | -0.5x | --- |
LianBio | 32.4M | -0.4x | --- |
Xilio Therapeutics Inc | 35.4M | -0.4x | --- |
Acurx Pharmaceuticals Inc | 35.8M | -1.9x | --- |
Company Information
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
Contact Information
- Headquarters
- 545 Concord Avenue, Suite 210CAMBRIDGE, MA, United States 02138
- Phone
- 857-702-9600
- Fax
- 734-293-0444
Executives
- Independent Chairman of the Board
- Andrew Koven
- President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
- Hyung Kim
- Chief Financial Officer
- Marshall Woodworth
- Independent Director
- Mark Glickman
- Independent Director
- Jason Groves
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 8.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.26 |
EPS | $-3.26 |
Book Value | $3.40 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
